Information de reference pour ce titreAccession Number: | 00004548-200312000-00017.
|
Author: | Pandey, Rajesh 1; Sharma, Anjali 1; Zahoor, A. 1; Sharma, Sadhna 1; Khuller, G. K. 1,*; Prasad, B. 2
|
Institution: | (1)Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh-160 012, India (2)EMID, CSIO, Sector 30, Chandigarh, India
|
Title: | |
Source: | Journal of Antimicrobial Chemotherapy. 52(6):981-986, December 2003.
|
Abstract: | Objectives: To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i.e. rifampicin, isoniazid and pyrazinamide encapsulated in poly (DL-lactide-co-glycolide) nanoparticles suitable for nebulization.
Methods: Drug-loaded nanoparticles were prepared by the multiple emulsion technique, vacuum-dried and nebulized to guinea pigs. The formulation was evaluated with respect to the pharmacokinetics of each drug and its chemotherapeutic potential in Mycobacterium tuberculosis infected guinea pigs.
Results: The aerosolized particles exhibited a mass median aerodynamic diameter of 1.88 +/- 0.11 [micro]m, favourable for bronchoalveolar lung delivery. A single nebulization to guinea pigs resulted in sustained therapeutic drug levels in the plasma for 6-8 days and in the lungs for up to 11 days. The elimination half-life and mean residence time of the drugs were significantly prolonged compared to when the parent drugs were administered orally, resulting in an enhanced relative bioavailability (compared to oral administration) for encapsulated drugs (12.7-, 32.8- and 14.7-fold for rifampicin, isoniazid and pyrazinamide, respectively). The absolute bioavailability [compared to intravenous (iv) administration] was also increased by 6.5-, 19.1- and 13.4-fold for rifampicin, isoniazid and pyrazinamide, respectively. On nebulization of nanoparticles containing drugs to M. tuberculosis infected guinea pigs at every 10th day, no tubercle bacilli could be detected in the lung after five doses of treatment whereas 46 daily doses of orally administered drug were required to obtain an equivalent therapeutic benefit.
Conclusions: Nebulization of nanoparticles-based ATDs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.
(C) Copyright Oxford University Press 2003.
|
Author Keywords: | poly(DL-lactide-co-glycolide); nanoparticles; antitubercular drugs; nebulization; tuberculosis.
|
References: | 1. Fauci, A. S. (2001). Infectious diseases: considerations for the 21st century. Clinical Infectious Diseases 32, 675-85.
2. Deol, P. & Khuller, G. K. (1997). Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochimica et Biophysica Acta 1334, 161-72.
3. Quenelle, D. C., Winchester, G. A., Staas, J. K. et al. (2001). Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrobial Agents and Chemotherapy 45, 1637-44.
4. Dutt, M. & Khuller, G. K. (2001). Therapeutic efficacy of Poly (DL-Lactide-Co-Glycotide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrobial Agents and Chemotherapy 45, 363-6.
5. Ahlin, P., Kristl, J., Kristl, A. et al. (2002). Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. International Journal of Pharmaceutics 239, 113-20.
6. Horisawa, E., Hirota, T., Kawazoe, S. et al. (2002). Prolonged anti-inflammatory action of DL-Lactide/Glycolide copolymer nanospheres containing betamethazone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharmaceutical Research 19, 403-10.
7. Jacobs, C. & Muller, R. H. (2002). Production and characterisation of a budesonide nanosuspension for pulmonary administration. Pharmaceutical Research 19, 189-94.
8. Dailey, L. A., Schmehl, T., Gessler, T. et al. (2003). Nebulization of biodegradable nanoparticles, impact of nebulizer technology and nanoparticle characteristics on aerosol features. Journal of Controlled Release 86, 131-44.
9. Anderson, J. M. & Shive, M. S. (1997). Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 28, 5-24.
10. Lamprecht, A., Ubrich, N., Hombreiro, P. M. et al. (1999). Biodegradable monodispersed nanoparticles prepared by pressure homogenisation-emulsification. International Journal of Pharmaceutics 184, 97-105.
11. Saito, H. & Tomioka, H. (1989).Therapeutic efficacy of liposome entrapped rifampicin against Mycobacterium avium complex infections induced in mice. Antimicrobial Agents and Chemotherapy 33, 429-31.
12. Scott, E. H. & Wright, R. C. (1967). Fluorimetric determination of isonicotinic acid hydrazide in plasma. Journal of Laboratory and Clinical Medicine 70, 355-60.
13. Gurumurthy, P., Nair, N. G. K. & Sarma, G. R. (1980). Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids. Indian Journal of Medical Research 71, 129-34.
14. Joshi, D. P., Lan-Chun-Fung, Y. L. & Pritchard, J. W. (1979). Determination of poly (vinyl alcohol) via its complex with boric acid and iodine. Analytica Chimica Acta 104, 153-60.
15. Ain, Q., Sharma, S. & Khuller, G. K. (2003). Chemotherapeutic potential of orally administered poly (lactide-co-glycolide) microparticles containing isoniazid, rifampicin and pyrazinamide against experimental tuberculosis. Antimicrobial Agents and Chemotherapy 47, 3005-7.
16. Sahoo, S. K., Panyam, J., Prabha, S. et al. (2002). Residual poly vinyl alcohol associated with poly (D, L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. Journal of Controlled Release 82, 105-14.
17. Dhuley, J. N. (1999). Aerosolized liposomal hamycin for treatment of systemic Candida infections in mice. FEMS Immunology and Medical Microbiology 25, 231-6.
18. Dalencon, F., Amjaud, Y., Lafforgue, C. et al. (1997). Atovaquone and rifabutin-loaded nanocapsules, formulation studies. International Journal of Pharmaceutics 153, 127-30.
19. Lopes, E., Pohlmann, A. R., Bassani, V. et al. (2000). Polymeric colloidal systems containing ethionamide, preparation and physicochemical characterization. Pharmazie 55, 527-30.
20. Suarez, S., O'Hara, P., Kazantseva, M. et al. (2001). Airways delivery of rifampicin microparticles for the treatment of tuberculosis. Journal of Antimicrobial Chemotherapy 48, 431-4.
21. Sharma, R., Saxena, D., Dwivedi, A. K. et al. (2001). Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharmaceutical Research 18, 1405-10.
|
Language: | English.
|
Document Type: | Original article.
|
Journal Subset: | Clinical Medicine. Life Sciences.
|
ISSN: | 0305-7453
|
NLM Journal Code: | hd7, 7513617
|
Annotation(s) | |
|
|